株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺癌の液体生検の世界市場:2017年~2021年

Global Lung Cancer Liquid Biopsy Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 586128
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
肺癌の液体生検の世界市場:2017年~2021年 Global Lung Cancer Liquid Biopsy Market 2017-2021
出版日: 2017年11月24日 ページ情報: 英文 109 Pages
概要

肺癌の液体生検について

液体生検は、患者の血液試料中の浮遊性腫瘍DNA(循環DNA)を同定するのに役立ちます。肺癌の液体生検は、上皮増殖因子受容体(EGFR)変異株および肺癌の原因である他の同定された変異株の検出にも役立ちます。肺の発癌性細胞を同定するために液体生検を用いるのは、肺癌の早期診断に役立つことが分かっています。

Technavioのアナリストは、2017年から2021年の期間に世界の肺癌の液体生検市場が17.15%のCAGRで成長すると予測しています。

当レポートでは、世界の肺癌の液体生検市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 イントロダクション

  • 市場概要

第5章 市場状況

  • 市場のエコシステム
  • 市場セグメンテーション分析

第6章 市場規模

  • 市場の定義
  • 市場規模(2016年)
  • 市場規模および予測(2016-2021年)

第7章 ファイブフォース分析

第8章 市場セグメンテーション:製品別

  • セグメンテーション:製品別
  • 比較:製品別
  • CTCs・ctDNA
  • エキソソーム・RNA
  • 市場機会:製品別

第9章 市場の分割:エンドユーザ別

  • セグメンテーション:エンドユーザ別
  • 市場シェア:エンドユーザー別
  • 臨床診断ラボ
  • 病院や診療所
  • 医師の研究室

第10章 地域状況

  • 地理別セグメンテーション
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • パートナーシップ契約の拡大
  • ベンダーの臨床試験への注力
  • 個別化治療のための液体生検の応用

第14章 ベンダー状況

  • 競合状況

第15章 主要なベンダー分析

  • Biocept
  • Exosome Diagnostics
  • F. Hoffmann-La Roche
  • QIAGEN
  • 注目すべき主要企業
  • 他の有力なベンダー

第16章 付録

  • 略語リスト
図表
  • Exhibit 01: Overview of tissue biopsy and liquid biopsy used for detection of lung cancer
  • Exhibit 02: Parent market
  • Exhibit 03: Market segments
  • Exhibit 04: Market size 2016
  • Exhibit 05: Global lung cancer liquid biopsy market 2016-2021 ($ millions)
  • Exhibit 06: Global lung cancer liquid biopsy market: Year-over-year growth 2017-2021 (%)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Global lung cancer liquid biopsy market by product 2016-2021 (%)
  • Exhibit 09: Comparison by product
  • Exhibit 10: Global lung cancer liquid biopsy market by CTCs and ctDNA: Market overview
  • Exhibit 11: Global lung cancer liquid biopsy market by CTCs and ctDNA 2016-2021 ($ millions)
  • Exhibit 12: Global lung cancer liquid biopsy market by CTCs and ctDNA: Year-over-year growth 2017-2021 (%)
  • Exhibit 13: Global lung cancer liquid biopsy market by exosomes and RNA: Market overview
  • Exhibit 14: Global lung cancer liquid biopsy market by exosomes and RNA 2016-2021 ($ millions)
  • Exhibit 15: Global lung cancer liquid biopsy market by exosomes and RNA: Year-over-year growth 2017-2021 (%)
  • Exhibit 16: Market opportunity by product
  • Exhibit 17: Market share by end-user
  • Exhibit 18: Global lung cancer liquid biopsy market by end-users 2016: Market overview
  • Exhibit 19: Global lung cancer liquid biopsy market by geography 2016-2021 (%)
  • Exhibit 20: Regional comparison
  • Exhibit 21: Lung cancer liquid biopsy market in Americas 2016-2021 ($ millions)
  • Exhibit 22: Lung cancer liquid biopsy market in Americas: Year-over-year growth 2017-2021 (%)
  • Exhibit 23: Top 3 countries in Americas
  • Exhibit 24: Lung cancer liquid biopsy market in EMEA 2016-2021 ($ millions)
  • Exhibit 25: Lung cancer liquid biopsy market in EMEA: Year-over-year growth 2017-2021 (%)
  • Exhibit 26: Top 3 countries in EMEA
  • Exhibit 27: Lung cancer liquid biopsy market in APAC 2016-2021 ($ millions)
  • Exhibit 28: Lung cancer liquid biopsy market in APAC: Year-over-year growth 2017-2021 (%)
  • Exhibit 29: Top 3 countries in APAC
  • Exhibit 30: Addressable market of lung cancer 2016
  • Exhibit 31: Limitations associated with the application of lung cancer liquid biopsy
  • Exhibit 32: Competitive structure analysis of global lung cancer liquid biopsy market 2016
  • Exhibit 33: Strategic success factors of companies in global lung cancer liquid biopsy market 2016
  • Exhibit 34: Biocept: Key highlights
  • Exhibit 35: Biocept: Strength assessment
  • Exhibit 36: Biocept: Strategy assessment
  • Exhibit 37: Biocept: Opportunity assessment
  • Exhibit 38: Exosome Diagnostics: Key highlights
  • Exhibit 39: Exosome Diagnostics: Strength assessment
  • Exhibit 40: Exosome Diagnostics: Strategy assessment
  • Exhibit 41: Exosome Diagnostics: Opportunity assessment
  • Exhibit 42: F. Hoffmann-La Roche: Key highlights
  • Exhibit 43: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 45: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 46: QIAGEN: Key highlights
  • Exhibit 47: QIAGEN: Strength assessment
  • Exhibit 48: QIAGEN: Strategy assessment
  • Exhibit 49: QIAGEN: Opportunity assessment
  • Exhibit 50: Biocartis: Company assessment
  • Exhibit 51: Siemens Healthcare: Company assessment
  • Exhibit 52: Global lung cancer liquid biopsy market: Other prominent vendors
目次
Product Code: IRTNTR15752

About Lung Cancer Liquid Biopsy

A liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. It is observed that the use of a liquid biopsy to identify carcinogenic cells of lungs will help in the early diagnosis of lung cancer.

Technavio's analysts forecast the global lung cancer liquid biopsy market to grow at a CAGR of 17.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer liquid biopsy market for 2017-2021. To calculate the market size, the report considers the sales and values of lung cancer liquid biopsy assays.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Lung Cancer Liquid Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocept
  • Exosome Diagnostics
  • F. Hoffmann-La Roche
  • QIAGEN

Other Prominent Vendors

  • AccuraGen
  • Agena Bioscience
  • BARD1
  • BGI
  • Biodesix
  • Bio-Rad Laboratories
  • Cancer Genetics
  • CellMax Life
  • Circulogene
  • CLEARBRIDGE BIOMEDICS
  • Cynvenio Biosystems
  • EntroGen
  • Epic Sciences
  • Epigenomics
  • Fluxion Biosciences
  • Freenome
  • Gencurix
  • Genetracer Biotech
  • Genomic Health
  • Grail
  • Guardant Health
  • HeliTec
  • Inivata
  • Lonza
  • MedGenome
  • Nanoview Diagnostics
  • Natera
  • Novogene
  • OncoCyte
  • OncoDNA
  • Pathway Genomics
  • Personal Genome Diagnostics
  • Predicine
  • Shuwen Biotech
  • Sysmex
  • Thermo Fisher Scientific
  • Transgenomic
  • Trovagene

Market driver

  • Rising incidence of lung cancer
  • For a full, detailed list, view our report

Market challenge

  • High cost of lab testing procedure
  • For a full, detailed list, view our report

Market trend

  • Vendors' focus on clinical trials
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2016
  • Market size and forecast 2016-2021

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Global lung cancer liquid biopsy market by CTCs and ctDNA
  • Global lung cancer liquid biopsy market by exosomes and RNA
  • Market opportunity by product

PART 09: MARKET SEGMENTATION BY END-USER

  • Segmentation by end-user
  • Market share by end-user
  • Clinical diagnostic laboratories
  • Hospitals and clinics
  • Physicians' office laboratories

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Lung cancer liquid biopsy market in Americas
  • Lung cancer liquid biopsy market in EMEA
  • Lung cancer liquid biopsy market in APAC
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Growing partnership agreements
  • Vendors' focus on clinical trials
  • Application of liquid biopsy for personalized treatment

PART 14: VENDOR LANDSCAPE

  • Competitive landscape

PART 15: KEY VENDOR ANALYSIS

  • Biocept
  • Exosome Diagnostics
  • F. Hoffmann-La Roche
  • QIAGEN
  • Key companies to watch
  • Other prominent vendors

PART 16: APPENDIX

  • List of abbreviations